Detection of cancer-specific peptides in prostate cancer using MHC tetramer technology by CHONG KIAN TAI
  
 
DETECTION OF CANCER-SPECIFIC PEPTIDES IN  
PROSTATE CANCER USING  
MHC TETRAMER TECHNOLOGY 
 
 
DR CHONG KIAN TAI 
MBBS (SINGAPORE), MRCS (EDINBURGH) 
 
 
A THESIS SUBMITTED FOR THE DEGREE OF  
MASTER OF SCIENCE 
 
 
DEPARTMENT OF SURGERY 






 Detecting cancer-specific peptides in prostate cancer   





I am grateful for the constant support, guidance and advice from John M. Corman, MD 
(Virginia Mason Medical Centre, Seattle, Washington, USA), William W. Kwok, PhD 
and Gerald T. Nepom, MD, PhD (Benaroya Research Institute at Virginia Mason, 
Seattle, Washington, USA) for the fruitful and academically stimulating research in 
USA.   
 
I am also grateful to my graduate programme supervisor A/Prof Kesavan Esuvaranathan 
and scientific advisor Dr Ratha Mahendran (Department of Surgery, National University 
of Singapore) for their constant support and guidance in my research progress in 
Singapore. 
 
I am also thankful for the wonderful teamwork and outstanding contributions from our 
clinical and laboratory colleagues without whom these studies will not be possible. 
 
Work in this thesis has received publishing permission from William W. Kwok, PhD, 
who has copyright ownership for the generation and use of MHC class II tetramers, 
data of mice and human tetramer staining studies, and data on phenotypic 




 Detecting cancer-specific peptides in prostate cancer   
using MHC tetramer technology 
 
3 
TABLE OF CONTENTS 
 
 TOPICS                      PAGE 
 
1. ACKNOWLEDGEMENT         2 
2. TABLE OF CONTENTS         3 
3. SUMMARY          6 
4. LIST OF TABLES           8 
5. LIST OF FIGURES          9 
6. LIST OF ABBREVIATIONS      11 
 
7. MAIN BODY OF THESIS  
 
(1) INTRODUCTION 
• Background of Prostate Cancer     12 
• T cells and Major Histocompatibility Complex  18 
• CD4+ T cells and Tumour Immunology   21 
• Tumour Antigens      25 
• Immunotherapy       27 
• Roles of MHC Class II Tetramers    31 
• Preliminary Data      36  
• Specific Research Goals     40 
 
 Detecting cancer-specific peptides in prostate cancer   
using MHC tetramer technology 
 
4 
 TOPICS                      PAGE 
 
(2) METHODS 
• Study design       41 
• Modifications of Tetramer staining protocols   42  
• Processing and stimulating PBMCs    44 
• Design and use of MHC Class II Tetramers   47 
• Measuring cytokine secretions     52 
• Typing of T cell Receptors (TcR)    52 
   
(3) RESULTS      
• Tetramer staining outcome     53 
• Background staining for controls    64  
• CD4+ T cell clones      66 
 
(4) DISCUSSION  
• Development of tetramer staining protocol   74 
• MHC Class II tetramer staining     76 
• Uses of peptide epitopes and antigen-specific T cells  81 
• Analyses of CD4+ T cell clones    84 
 
(5) CONCLUSION AND FUTURE DIRECTIONS   87 
  
 Detecting cancer-specific peptides in prostate cancer   
using MHC tetramer technology 
 
5 
 TOPICS                      PAGE 
 
8. BIBLIOGRAPHY        88 
9. APPENDICES   
(1) Appendix A - Original Tetramer staining protocol   94 
 
(2) Appendix B -  Revised protocol for processing PBMC   96 
(DRB1*0401 Tetramer Binding) 
 
(3) Appendix C -  MHC Class II tetramer staining protocol from 99 
   Benaroya Research Institute at Virginia Mason 
 
(4) Appendix D -  General T-cell Clone Growing protocol   102 
 








 Detecting cancer-specific peptides in prostate cancer   





Prostate cancer is the 5th most common male cancer in Singapore and the most common 
non-cutaneous malignancy in North American men.  Serum prostate specific antigen 
(PSA) is the most common serum marker used for prostate cancer diagnosis, prognosis 
and disease monitoring after therapy.  However, it is not prostate cancer-specific and 
does not have high specificity or sensitivity. 
 
The PSA protein has antigenic sequences that induce T-cell responses.  Amongst T-
lymphocytes, CD4+ T-cells are highly specific in recognition of peptide antigens 
presented by major histocompatibility complexes (MHC) class II molecules and vital for 
secondary expansion and activation of cytotoxic T cells.  Hence CD4+ T-cells recognise 
peptide-specific antigens and co-ordinate the immune repertoire to attack cells with 
foreign antigens for eventual cellular lysis.  Unfortunately its MHC-peptide-T cell 
receptor complexes are of low serum frequency and low binding avidity.   
 
MHC tetramers are soluble recombinant human leucocyte antigen (HLA) molecules that 
bind to specific peptide antigens.  They enable surrogate interactions with antigen-
specific T-cell receptors even in the absence of antigen-presenting cells.  Highly specific 
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This study applied MHC class II tetramers to screen for new prostate specific CD4+ T-
cell responsive epitopes in peripheral blood leucocytes of prostate cancer patients.  
 
CD4+ T cells were isolated and stimulated in vitro with test peptides from DRB1*0401, 
DRB1*0701 and DRB1*1501 prostate cancer patients and non-cancer controls.  
Fluorophobe-labelled MHC class II tetramers loaded with specific test peptides assessed 
the presence of antigen specific T cells by cell flow cytometry.   
 
The results in DRB1*0401 volunteers showed that PAGE-113-25, a prostate associated 
cancer-testis antigen, was identified in this highly specific interaction for both prostate 
cancer patients and normal controls.  Further study is needed to define its role in allele-
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BACKGROUND OF PROSTATE CANCER 
 
Prostate cancer is the 5th most common male cancer in Singapore, affecting 7.2% of all 
male cancers between 1998 and 2002 (Figure 1).  Its age-standardised rate had increased 
four-fold from 4.2 per 100,000 per year between 1968 and 1972 to 17.4 per 100,000 per 
year between 1998 and 2002.  It occurs mostly in men after 50 years old and has the 
highest average annual percent rate of increase for age-standardised incidence rate at 
5.6% between 1968 and 2002 (Figure 2) [1].   
 
Figure 1:  Top ten most frequent male cancers in Singapore  























Percentage of all male cancers
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Figure 2:  Age-standardised rates between 1968-2002 (top) and age-specific rates 
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Prostate cancer is also the most common non-cutaneous male cancer in North America, 
affecting one in every six men.  The American Cancer Society estimates 234,460 new 
prostate cancer cases in year 2006 with 27,350 prostate-cancer specific deaths [2].   
 
The Surveillance, Epidemiology and End Results (SEER) programme from the National 
Cancer Institute (NCI) in USA is a comprehensive cancer registry database to collect and 
track cancer incidence and survival statistics in different population-based registries 
throughout USA [3].  Although prostate cancer has maintained its lead in cancer 
incidence in North America, the SEER database showed a gradual decrease in new 
prostate cancer detection from the peak in early 1990’s recorded in 9 registries between 
1975 and 2003 (Figure 3). 
 
When compared to the USA, the trend in detecting new prostate cancers in Singapore 
appears to be rising without any signs of reaching a plateau currently.  It is vital for us to 
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 Figure 3:   SEER Age-adjusted incidence rates by race for all prostate cancer  
   (SEER 9 Registries for 1975-2003; Age-Adjusted to the year 2000  
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Currently, clinicians have limited tools to test for prostate cancer.  These tools include 
clinical digital rectal examination (DRE) to palpate the prostate, serum prostate specific 
antigen (PSA), and histological analysis of prostate tissues obtained by prostate needle 
biopsies.   
 
Prostate specific antigen is a serine protease from the kallikrein gene family [4].  It is 
produced by the normal male prostatic epithelium and periurethral glands.  However its 
serum level is elevated in several prostatic diseases, which range from non-malignant 
conditions including the benign prostatic hyperplasia, prostatic inflammation or 
infections, to malignancies like prostate cancers.  Hence, even though serum PSA is the 
most common serum biomarker used for prostate cancer diagnosis, prognosis and disease 
monitoring after therapy, it does not have high specificity or sensitivity because it is not 
prostate cancer-specific. 
 
The PSA era has led to increased diagnosis of early-staged prostate cancer, but stage-for-
stage cancer-specific mortality has unfortunately remained similar to decades ago.  
Despite the widespread use of serum PSA, patients with apparently normal PSA values 
may also have histologically-proven prostate cancer from transrectal prostatic needle 
biopsies [5].  This problem is highlighted when up to 25% of men with prostate cancer 
have PSA within the ‘normal range’ of less than 4.0 ng/ml [6].  
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In view of the limitations of PSA, population screening for prostate cancer has come 
under scrutiny [7].  The exceptions for effective cancer screening may only apply to high-
risk groups for prostate cancer, including African-Americans ethnicity, strong family 
history of prostate cancer, and age of the patient.  
 
Prostate cancer screening is further limited by the high false-negative first needle biopsy 
rate.  One-third of patients are not diagnosed from single-session needle biopsy due to 
potential sampling errors.  In addition, prostate needle biopsies are invasive procedures 
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T CELLS AND MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) 
 
T lymphocytes defend against intracellular micro-organisms and activate other cells like 
B lymphocytes and macrophages.  To achieve intercellular interactions, T cell receptors 
(TcRs) recognise cell-associated antigens with high specificity through proteins encoded 
by major histocompatibilty complex (MHC) locus.  The TcR is highly specific in peptide 
antigen binding before forming a complex with the MHC molecules on the target cell. 
 
The MHC locus located on chromosome 6 at 6p21.3 is in one of the most gene-dense 
regions of the human genome.  It encodes some of the most polymorphic human proteins 
in MHC class I and II molecules, which may contain over 200 allelic variants.  With 
complete gene sequencing by the MHC Sequencing Consortium in 1999, linkage 
disequilibrium and genomic polymorphisms of the MHC genes are better understood for 
future applications [8].   
 
Segments of genes in the MHC locus encode cell surface-specific proteins in human, 
known as the human leucocyte antigens (HLA).  Traditionally, these refer to 3 main 
MHC regions: the centromeric class II, the telomeric class I with the class III region in 
between them.  The HLA-A, HLA-B, HLA-C genes belong to MHC class I molecules, 
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The two main types of MHC gene products are the class I and class II molecules.  The 
MHC class I molecules are heterodimers consisting of a single transmembrane α-chain, a 
β2-microglobulin and an antigenic peptide within the α1-α2 cleft needed for its stable 
expression to present peptides to the CD8+ cytolytic T cells.  These peptides are derived 
from cytosolic proteins which have been degraded by proteasome from larger 
intracellular proteins.   
 
The MHC class II molecules are found on antigen presenting cells, like dendritic cells, 
macrophages, activated T cells and B cells.  They are heterodimers composed of two non-
covalently associated homologous peptides, the α-chain and β-chain, which present 
extracellular proteins to CD4+ helper T cells.   
 
The MHC class III region contains genes that encode for complement components of 
inflammation (e.g. C2, C4) and tumour necrosis factor (TNF) superfamily. 
 
The nomenclature for HLA system had been updated regularly by the IMGT/HLA 
Database, which is part of the international ImMunoGeneTics (IMGT) project that 
operates as a high-quality resource centre for immunoglobulins, T cell receptors, major 
histocompatibility complex, immunoglobulin superfamily (IgSF), major 
histocompatibility complex superfamily (MhcSF) and related proteins of the immune 
system (RPI) of human and other vertebrate species [9].  It provides a specialist database 
for updated sequences of the human major histocompatibility complex (HLA).   
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This database also includes the official sequences for the World Health Organisation 
(WHO) Nomenclature Committee for Factors of the HLA System.  As of Dec 2006, there 
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CD4+ T-CELLS AND TUMOUR IMMUNOLOGY 
 
In adaptive immunity, T cells play a key role in specific recognition of and response to 
foreign peptide antigens, with the collaboration of MHC-restricted peptide bearing 
antigen-presenting cells.  During cell-mediated immunity, CD4+ T cells activate 
macrophages for phagocytosis while cytotoxic CD8+ T cells achieve targeted cell lysis.  
For humoral immunity, CD4+ T cells stimulate proliferation and differentiation of B 
lymphocytes. 
 
The unique properties of T cells include recognising only specific amino acid sequences 
of peptides and protein antigens.  These antigen-specific T cells respond to foreign 
peptides only if these antigens are attached to cell surfaces of antigen presenting cells 
(APCs) of the particular individual.  This process, known as self MHC restriction, affects 
both the CD4+ and CD8+ T cells.  
 
The formation of TcR-peptide-MHC complex is therefore highly regulated and this 
allows for appropriate T cell activation and function.  Hence, MHC Class II-restricted 
CD4+ T cells recognise extracellular proteins that have been internalised into the vesicles 
of APCs, with the help of co-stimulators like interferon-γ and CD40-CD40L interactions.  
Similarly, CD8+ class I-restricted T cells recognise peptides specifically degraded from 
cytosolic proteins that have undergone endogenous synthesis. 
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The T lymphocytes gain their unique functions from the lymphocytic maturation process.  
Immature precursor cells in the bone marrow do not express antigen receptors until they 
develop into mature lymphocytes in the peripheral lymphoid tissues.  By the time they 
mature, T cells have undergone sequential gene expression, generated diverse repertoire 
of antigen receptor specificity and received functional and phenotypic characteristics that 
are unique to their subtypes.   
 
To ensure useful antigen receptor specificities are preserved in T cells, positive selection 
of T cells whose receptors bind with weak and low avidity to self MHC molecules in the 
thymus reach eventual T cell maturation.  They are rescued from programmed cell death.   
 
However, developing T cells with TcRs that do not recognise any thymic MHC 
molecules are eliminated by apoptosis.  Alternatively, if developing T cells with TcRs 
that bind too strongly to self MHC antigens, they are also eliminated by apoptosis 
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The end result of T cell maturation in the thymus is the formation of naïve mature T 
lymphocytes.  Once released to peripheral lymphoid organs, the T cells will be activated 
if their TcRs recognise specific antigens found on peptide-MHC complexes carried by 
antigen presenting cells.  Upon activation in the presence of co-stimulators with cytokine 
signals, these T cells proliferate and differentiate into memory and effector T cells.   
 
For the CD4+ T cells, effector T cells like T-helper (TH) cells will secrete cytokines, 
activate B cells and help macrophages in phagocytosis.  Effector T cells differentiate into 
various subsets from mature CD4+ T cells to perform different effector functions.  The 
TH1 cell lineage produces interferon-γ (IFN-γ) to combat microbials that activate 
macrophages and natural killer cells, while the TH2 lineage secretes interleukin-4 (IL-4) 
and interleukin-5 (IL-5) in the presence of helminthic worms and allergens.  It is 
important that these activated T-cell responses are reduced when antigens have been 
eliminated.  This is a normal process to ensure antigen-activated T cells undergo 
apoptotic cell death and return the immune system to baseline homeostasis. 
 
As for memory T cells, they survive long after the elimination of antigen stimulation and 
are responsible for better and stronger secondary immune responses during future 
exposures to the same antigen.  Unfortunately, the mechanisms, maintenance and 
stimulation of CD4+ memory T cells are not well understood. 
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The idea of an immune system that seeks out and destroys developing cancer cells leads 
to the concept of immune surveillance.  In clinical practice, there is an increase in cancer 
incidence of melanoma, Kaposi sarcoma and liver cancer in kidney transplanted patients 
who received immuno-suppression treatment [10-11].  In patients with breast cancer and 
melanoma, they have longer cancer-specific survival if histopathology analysis showed 
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Tumours antigens that are expressed exclusively on tumour cells and not on normal host 
cells are known as tumour-specific antigens, while those that are also expressed on 
normal cells are called tumour-associated antigens.  These antigens may be products of 
oncogenes or tumour suppressor genes, silent genes in normal tissues that had abnormal 
expression, over-expressed genes or oncogenic viruses.   
 
Some of them may be differentiation antigens normally found in its tissue of origin, like 
the serum prostate specific antigen, while other antigens are oncofoetal proteins that are 
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 Table 1: Examples of tumour antigens in human 
 
Types of antigens Examples of tumour antigens 
 
Mutated oncogenes  Her-2/neu (breast cancer),  
Ras mutation 
 
Mutated tumour suppressor genes Rb gene (retinoblastoma)  
p53 mutation (stomach, bladder cancer) 
 
Over-expressed cellular proteins Tyrosinase,  
Melanoma-antigen recognised by T cells 
(MART in melanocytes) 
 
Mutated genes that were silent in 
normal adult tissues 
Melanoma antigen genes (MAGE in 
melanoma),  
GAGE proteins (melanoma),  
cancer-testes antigens 
 
Oncofoetal proteins Carcinoembryonic antigen (colon cancer),  
alpha-foetal protein (liver cancer) 
 
Oncogenic viruses Human papilloma virus (cervical cancer), 
Epstein-Barr virus (nasopharyngeal cancer) 
 
Differentiation antigens at tissue of 
origin 
Prostate-specific antigen (prostate cancer), 
CD20 (B cell lymphoma) 
 
Mutated glycolipid and glycoprotein 
antigens 
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Tumour immunotherapy is a potential tool to eliminate cancer cells by inducing cancer-
specific T cells to inhibit tumour growth.  Amongst various strategies to develop 
vaccines, one of the goals is to identify the most immunogenic antigen or peptide epitope 
of the malignancy.  These peptides are short amino acid branches that will be synthesised 
for mass production.  They are weakly immunogenic but will mount a stronger immune 
response if it is coupled to larger proteins.   
 
Currently the majority of peptide-based immunotherapy is focused on MHC class I 
restricted antigen epitopes against tumour antigens.  Tumour-specific cytotoxic T 
lymphocytes (CTLs) were isolated from cancer specimens.  Anti-tumour CTLs were 
effective in animal studies using viral-induced murine models.   
 
Tumour cells or peptides are ingested by the host antigen presenting cell and presented on 
its cell surface as bound peptide to MHC class I molecules.  This process is called cross-
presentation, where antigen presenting cells migrate to draining lymph nodes and present 
peptide antigen-MHC Class I molecule complex antigen-specific CD8+ T cells.  This 
leads to either activation or tolerisation of CD8 T cells. The CD8+ T cells received 
signals from the APC and differentiate into anti-tumour cytotoxic T lymphocytes for 
tumour-specific cell kill.  These MHC class I restricted antigen epitopes include Her-
2/neu epitopes in breast cancer [13] and MAGE-3 epitopes in melanoma [14].   
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The most important antigen-presenting cell is the dendritic cell, although B cells and 
macrophages have similar functions.  Through phagocytosis and intracellular transport of 
MHC class I-peptide antigen complex towards the cell surface, the antigen presenting 
cells become detected by antigen-specific CD8 T cells. 
 
In contrast, the exact roles of CD4+ T cells in tumour immunology are less frequently 
studied.  They may secrete tumour-specific cytokines, activate macrophages or help to 
activate CD8+ T cell functions. 
 
The prostate specific antigen (PSA) protein has antigenic sequences that induce T cell 
responses.  Amongst T lymphocytes, CD4+ T cells are highly specific in recognising 
peptide antigens presented by major histocompatibility complexes (MHC) class II 
molecules.  Quantification of CD4+ T cells that recognise specific prostate peptides may 
be a key to prostate cancer-specific diagnosis and management.   
 
Prostate cancer is a weakly immunogenic tumour.  The antibody titres to PSA were 
higher in patients with developed prostate cancer when compared to healthy controls [15].  
For prostate cancer, most of these peptide vaccines research were also based on MHC 
class I binding peptides, including work on prostate specific antigen (PSA) and prostate 
specific membrane antigen (PSMA) proteins [16].   
 
Using computer based algorithms to predict peptide sequences from PSMA that can 
stimulate antigen-specific cytotoxic T lymphocytes, only one of five peptides PSMA27 
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was able to induce CTLs that effectively identified prostate cells expressing HLA-A2 and 
PSMA molecules [17].  However, there is limited published literature in detecting 
prostate cancer specific CD4+ T cells tumour antigenic epitopes to induce immunity. 
 
In anti-tumour immunity, CD4+ T cells are important for secondary expansion and 
activation of CD8+ T cells [18].  Although generation of CTLs may not need antigen-
specific CD4+ T cells, they were needed to maintain CD8+ T cell numbers and allow 
infiltration of CD8+ T cells into tumours [19].   
 
An approach to rational peptide-based vaccine design is to incorporate knowledge of 
tumour-specific MHC class II-restricted antigen presented to CD4+ T cells.  
Identification of key MHC class II epitopes on tumour cells by the CD4 + T cells will 
activate cancer-specific recognition of cancer cells as foreign destined for immune 
destruction.  These CD4+ T cells will subsequently activate macrophages and CD8+ T 
cells for tumour-specific cytotoxic cell lysis. 
 
However detection of antigen-specific CD4+ T cells is difficult due to their low serum 
frequency and low binding avidity on its MHC-peptide-TCR complexes.   
 
There are several methods to study in vivo functions of the antigen-specific T cells.  The 
use of a surrogate MHC-peptide loaded tetramer can isolate T cells with single antigen 
specificity.  It is made up of a MHC molecule attached to biotin by recombinant DNA 
technology.  Four biotin-conjugated MHC molecules are bound to central avidin core that 
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is loaded with fluorochrome.  To study the role of a peptide in activated T cells, it is 
loaded onto the MHC molecule to bind onto T cell receptors of the antigen-specific T 
cells, thereby forming a peptide-MHC tetramer.  
 
MHC class I tetramers are more stable in vitro with only one polymorphic polypeptide 
chain.  Compared to its counterpart, the MHC class II molecules have 2 polymorphic 
chains and it is more difficult and unstable to assemble MHC class II tetramers to study 
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ROLES OF MHC CLASS II TETRAMERS 
 
The use of MHC tetramer technology to track epitope-specific T cells started with 
identifying HLA-specific class I restricted epitopes [20].  Tetrameric MHC class I-
peptide complexes detected antigen specific CD8+ T cells in peripheral blood samples 
because of its higher affinity to T cell receptors (TcRs) compared to monomeric MHC-
peptide complexes.  The fluorochrome attached to the tetrameric MHC-peptide 
complexes allowed direct visualisation of these T cells that recognise peptide-specific 
MHC-peptide complexes [21]. 
 
The only feasible way to detect and identify peptide-specific epitopes in human that are 
recognised by CD4+ T cells is through the use of MHC class II tetramers.  These MHC 
tetramers are recombinant HLA molecules with specific bound peptides antigens, thereby 
acting as surrogate MHC-peptide ligands on the antigen presenting cells [22].  They have 
been used in disease-specific T-cell epitope detection in autoimmune diseases like Type 1 
diabetes mellitus and relapsing polychondritis [23-24].   
 
MHC class II molecules used for tetramer staining allow direct visualisation of antigen-
specific T cells in a mixed population.  It allows concurrent phenotyping of antigen-
specific T cells, especially for cytokine secretion profile, surface antigen, etc.).  In 
addition, tetramer staining allows direct cloning of antigen-specific T cells via single cell 
sorting protocols. 
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The development of MHC class II tetramers ensures proper tracking antigen-specific T 
cells.  Mapping antigenic epitopes using these tetramers are tested for potential peptide 
epitopes for any given MHC restriction. 
 
Once knowledge of immuno-dominant epitopes provides basis for directed 
immunotherapies, it provides a scientific tool for peptide vaccines to be used on treatment 
plans to allergens, autoimmune diseases and cancers. 
 
The most frequently expressed HLA class II allele in North American men is the HLA-
DRB1*0401 allele, occurring in up to 20% of the North American population.  Other 
frequent alleles include DRB1*0701 and DRB1*1501 alleles.  The current study done in 
USA concentrates on detecting antigen-specific CD4+ T cells in HLA-DRB1*0401 
prostate cancer patients with the use of MHC Class II tetramers.  Identifying these T cell 
epitopes for prostate cancer can facilitate vaccine development and potentially apply 
these epitope-specific CD4+ T cells as a useful immunological marker to monitor 
prostate cancer progression.  
 
In the Singapore Cord Blood Registry, the most frequent Singapore Chinese DRB1 
alleles are DRB1*0901 and DRB1*1501 [25]. A review of the Singapore Malay 
population showed that DRB1*1202 and DRB1*1502 accounted for 57% of its gene 
frequencies [26]. 
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Soluble MHC-peptide class II molecules had also successfully identified epitope-specific 
T cells in murine class II restricted models [27] and in human antigen-specific CD4+ T 
cells in human peripheral blood [28].  To generate MHC class II tetramers, peptides were 
loaded on empty biotinylated recombinant class II molecules before adding PE-labelled 
streptavidin.   
 
The Benaroya Research Institute at Virginia Mason (Seattle, Washington, USA) is 
designated by the National Institutes of Health and Immune Tolerance Network as a 
"Tetramer Core Laboratory" in USA.  It has pioneered the use of MHC class II tetramers 
in the management of insulin-dependent diabetes mellitus [29].  These MHC class II 
tetramers are soluble recombinant human leucocyte antigen (HLA) molecules that bind to 
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 Figure 4: MHC class II tetramer with 4 biotin molecules attached to central  
   Strepavidin (S) core and labelled with fluorochrome PE.   
 
   Test peptide being studied is bound to the extracellular portion of α  
   and β-polymorphic polypeptide chains. 
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These molecules enable surrogate interactions with antigen-specific T cell receptors, 
independent of the presence of antigen-presenting cells.  Using these MHC class II 
tetramers, our study analysed the presence and roles of highly-specific MHC class II-
peptide antigen complexes in CD4+ T cells from prostate cancer patients. 
 
There are 3 major advantages for using tetrameric class II-peptide complexes to study 
human T cells: 
 
1) Qualitative analysis to detect the presence of epitope-specific CD4+ T 
cells in human peripheral blood mononuclear cells, 
2) Quantitative analysis of the amount and frequency of epitope-specific 
CD4+ T cells in human peripheral blood mononuclear cells, 
3) Epitope-specific CD4+ T cells can be cloned by single-cell sorting for T 
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Preliminary unpublished data by John Gebe, PhD and William W. Kwok, PhD in the 
laboratory showed that DR0401/PSA 64-78 tetramer stained PSA 64-78 responsive T cells.  
HLA DR0401 transgenic mice were immunised subcutaneously at the base of the tail 
with either 100 µg of influenza HA 307-319 peptide or 100 µg of PSA 64-78 peptide in the 
presence of 50% Complete Freunds Adjuvant (CFA/PBS).   
 
Mice were sacrificed after 7 days and purified T cells from draining lymph nodes were 
stained with PE-labeled DR0401/HA or DR0401/PSA class II tetramers.  Flow cytometry 
results showed that only the T cells from the PSA 64-78 immunised mice gave six-fold 
increase in positive staining with the DR0401/PSA tetramers at 0.19%.  
 
No significant staining could be observed with the DR0401/HA tetramers in the PSA 
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Figure 5:  DR0401/PSA64-78 tetramer binding to DR0401 transgenic  
  mice immunised with the (A) HA307-319 or (B) PSA64-78 
  peptides.  Mice were immunised with 100 µg peptide in  
  50% CFA/PBS at the base of its tail.   
 
  Draining lymph nodes were harvested on day 7 and stained  
  with DR0401/PSA64-78 tetramers for 2.75 hr at 37ºC.  
  CD4 and CD44 antibodies were added and incubated with  
  ice for another 15 minutes.   
 
  There is a six-fold increase in positive staining with  the 
  (B) DR0401/PSA64-78 tetramers (0.19%) when compared to  
  the (A) control DR0401/ HA307-319 tetramers (0.03%). 
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In the clinical setting, valid informed consents and whole blood were taken from one 
prostate cancer patient and one volunteer normal control.  Four million peripheral blood 
mononuclear cells (PBMCs) were isolated from a prostate cancer donor (HLA 
DRB1*0401, DRB1*1501) and a control volunteer (HLA DRB1*0401, DRB1*0102) 
before co-stimulation with PSA64-78 peptide (10 µg/ml).   
 
After 12 days, T cells from the cancer patient were recognised by the DR0401/ PSA64-78 
tetramer with six-fold increase in tetramer staining intensity, as compared to minimal 
background staining with the control DR0401 binding peptide VP16472-484. 
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JoFa PSA2 peptide Stim 0.5% 4.8%
39.9% 54.8%




















KeDe PSA2 peptide Stim 
0.2% 0.8%
40.3% 58.6%























































































































































Figure 6:  DR0401/PSA64-78 tetramer binds to CD4+ human T  cells.
  PBMCs from a (A) matched DR0401 control volunteer 
   and a (B) DR0401 prostate cancer patient were obtained 
  and cultured in a 24-well plate.   
 
  On day 12, cultured cells were stained with the 
  DR0401/PSA64-78 tetramers for 2.75 hr at 37ºC.  Anti-CD4 
   was added and incubated on ice for an additional 15 
   minutes before cell sorting. 
 
  There is a six-fold increase in positive staining with  the
  (B) DR0401 cancer patient (4.8%) when compared to 
  the (A) DR0401 control (0.8%). 
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SPECIFIC RESEARCH GOALS 
 
Before embarking on this study, there was no known established protocol to study 
cancer-specific peptide recognition using the MHC class II tetramers in prostate cancer.  
These tetramers had been used to identify autoreactive CD4 T cells in autoimmune 
conditions but had not been used in cancers.   
 
The primary research goal of this current study is to utilise these MHC class II tetramers 
to develop new protocols to identify antigen-specific CD4+ T cells in prostate cancer 
patients.  The secondary goal is to screen for novel cancer-specific CD4+ T-cell epitopes 
that can detect prostate cancer-specific peptides.   
 
The eventual goal is to identify novel peptides that can supplement or even replace serum 
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STUDY DESIGN  
 
Research and database protocols were approved by the Institutional Review Board with 
compliance to USA’s Health Insurance and Portability Accountability Act (HIPAA) 
guidelines at both Virginia Mason Medical Center and Benaroya Research Institute at 
Virginia Mason in Seattle, Washington, USA.  Patients who gave voluntary informed 
consent were HLA-typed.   
 
The more common frequencies of DR alleles in North America are HLA DR0401, 
DR0101, DR0301, DR0701, DR1501 and DR0404, which account for 60% of the US 
Caucasian population.  Hence, in this study, peripheral blood lymphocytes were obtained 
from DRB1*0401, DRB1*0404, DRB1*0701 and DRB1*1501 prostate cancer patients 
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MODIFICATION OF TETRAMER STAINING PROTOCOLS  
 
Prior work to identify epitope-specific CD4+ T cells had been on insulin-dependent 
diabetes mellitus and autoimmune diseases.  There was no previous work that 
investigates cancer-specific epitope detection in CD4+ T cells in malignancies using 
MHC class II tetramers.  Hence the original protocol was adapted at the start of the study 
(see Appendix A). 
 
In the original protocol, PBMCs were primarily stimulated with the test peptide.  After 10 
days of expansion, HLA-DR monomer loaded with the test peptide was added for 
secondary stimulation [24].  At 3 to 6 days later, HLA-DR tetramer shows an increased 
detection of signal intensity of MHC class II tetramer-peptide-TcR complexes, when 
compared to the absence of secondary stimulation.  Tetramer staining with anti-CD25 T 
cell activation marker was assessed by cell cytometry on Day 13 and 16 from primary 
CD4+ T cell stimulation to detect the highest positive staining activities.  
 
At the start of the study we compared the absence and presence of HLA-DR0401 class II-
monomer on tetramer staining activity using the PMBCS from the same DR0401 prostate 
cancer volunteer.  Day 13 and 16 tetramer staining was more intense in cells which did 
not undergo secondary stimulations, suggesting that secondary clonal expansion may 
adversely affect the frequency of activated  CD4+ T cells.   
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In subsequent donors, we analysed different T cells for their MHC class II tetramer 
staining to understand if the peptide-MHC presented are recognised by the TcRs of these 
T cells.  Instead of PBMCs, the primary stimulation in vitro with test peptides was done 
in cell-sorted mononuclear cells that had undergone fluoroprobe-labelled cell sorting 
from Day 1.   
 
Four categories of PBMCs were sorted for primary peptide stimulation:  
• CD4+ T cells 
• CD4+CD25- T cells to remove potential confounding T regulatory or T 
suppressor effects 
• CD4+CD25-CD45RA+ naïve T cells, and  
• CD4+CD25- CD45RA- memory T cells. 
 
The aim is to detect any differences in peptide recognition, if any, in these categories of 
activated CD4+ T cells after in vitro peptide stimulation and proliferation.  Depending on 
the cell morphology on the cell culture wells, tetramer staining was done between Day 13 
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PROCESSING AND STIMULATING PBMCs 
 
The revised protocol for the study is listed in Appendix B.  After collecting 150 mls of 
heparinised whole blood from the donor’s cubital fossa, peripheral blood mononuclear 
cells (PBMCs) were isolated with Ficoll-Hypaque gradient and cell separation with 
antibody-labelled magnetic beads (MACS microbeads, Miltenyi Biotec, Germany).   
 
Cells were cultured in RPMI-1640 (GIBCO, Rockville, Maryland, USA), supplemented 
with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 µg/mL penicillin/streptomycin and 
15% pooled human serum.   
 
Adherent cells were prepared by plating PBMC at 2.5 × 106 cells per well in 24-well 
plates for 1 hour.  Non-adherent cells were removed using a transfer pipette.  Adherent 
cells were incubated with 10 µg/mL of respective test peptide. 
 
In view of potential conflicting T regulatory or suppressor abilities, CD4+CD25+ T cells 
were not used for cell cultures [30].  Only CD4+CD25- T cells were cell sorted using the 
fluorescence-activated cell sorter by flow cytometry (Becton Dickinson FACSCalibur 
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A density of 2.5 million cells per well of PBMCs underwent primary exogenous peptide 
stimulation with the study test peptide at a final concentration of 10 µg/ml.  These cells 
were co-cultured with irradiated autologous antigen presenting cells prepared as adherent 
cell fractions in 24-well plates as per protocol listed in Appendix B.  No additional GM-
CSF, IL-4 or activating reagents were placed.  The 24-well plates were incubated at 37ºC 
between 13 to 17 days with scheduled interval IL-2 co-stimulation.   
 
Figure 7 shows a summary of events from PBMC processing to MHC class II tetramer 
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 Figure 7:  Processing of peripheral blood mononuclear cells (PBMCs) for  
   primary peptide stimulation and MHC class II tetramer staining for  
   analysis by flow cytometry.  
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DESIGN AND USE OF MHC CLASS II TETRAMERS 
 
To construct the expression vectors to generate MHC class II soluble DR0401 
(DRA*0101/DRB1*0401) molecules, biotinylation sequence was added to the 3' end of 
the DRB1*0401 leucine zipper cassette before the chimeric cDNA was subcloned into a 
Cu-inducible Drosophila expression vector.  DR-A and DR-B expression vectors were 
co-transfected into Schneider S-2 cells.  Purified DR0401 molecules were biotinylated 
and loaded with test peptides to form tetramers by adding PE-streptavidin [28].   
 
Short segment test peptides with higher affinity were predicted from TEPITOPE 
prediction programme that include prostate specific antigen (PSA), prostate specific 
membrane antigen (PSMA), prostatic acid phosphatase (PAP), prostate associated gene 
(PAGE-1), NY-ESO-1 and melanoma associated gene (MAGE-3) peptides in view of 
their association with prostate cancer in published literature [31-35].   
 
These peptides were 12 to 15 amino acids in length and were synthesised in our 
institution.  Synthesised peptides were loaded into the soluble MHC class II molecules 
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1. Prostate specific antigen 
 
  PSA 49-63  PSA 64-78 




   NY-eso 119-138 NY-eso 120-131 
 
3. Prostatic acid phosphatase 
 
  PAP 22-34  PAP 225-236 
 
4. Prostate specific membrane antigen 
 
  PSMA 102-114 PSMA 356-366 
  PSMA 433-444 PSMA 459-473 
  PSMA 638-649 
 
5. Cancer-testis antigens 
 
  MAGE-3 146-160 
 
  PAGE-1 13-25 PAGE 6-18 
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Between 13 and 17 days after the stimulation with the test peptides, T cells were stained 
with the corresponding peptide-loaded MHC class II tetramers.  T cells were stained with 
PE-labelled tetramer and combinations of fluorochrome-labeled anti-CD3, anti-CD4, 
anti-CD25 (PharMingen; Becton Dickinson Immunocytometry Systems, San Jose, 
California, USA) and analysed by flow cytometry.   
 
The 4 categories of CD4+ T cells, CD4+CD25- T cells, CD4+CD25-CD45RA+ naïve T 
cells and CD4+CD25-CD45RA- memory CD4+ T cells (labelled as CD45RO) primarily 
stimulated in vitro with test peptides were analysed using PE-labelled MHC class II 
tetramers loaded with these specific test peptides.  This was done between day 13 and 17 
after primary stimulation, dependent on the cell morphology in the culture plates for their 
viability.   
 
Tetramers staining protocol was done to detect the presence of antigen specific CD4+ T 
cells by cell flow cytometry.  PE-labelled HLA-DR tetramer (0.5 µg/ml) was added to 
make a final concentration of 10 µg/ml for 2 hours at 37ºC for FACS analysis.  
 
Positive tetramer staining of T cells represented recognition of peptide-specific CD4+ T 
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Levels of background staining, generally around 0.1%, were determined by using 
tetramers loaded with an irrelevant peptide, HA307–319 (influenza A hemagglutinin protein, 
residues 307–319) as positive control and empty tetramer as negative control. 
 
Tetramer-positive staining CD4+ T cells were single-cell sorted to obtain antigen specific 
T cell clones for analysis and assess the phenotypic characteristics of these T cells.  They 
were single-cell sorted into 96-well U-bottom plates by using a Becton Dickinson 
FACSVantage cell sorter (San Jose, CA) on the same day (see Appendix D).  
 
Sorted CD4+ T cells were expanded with 1.5 x 105 unmatched, irradiated (5000 rad) 
PBMCs per well as feeders.  T cell stimulation with 2.5 µg/ml phytohemaglutinin (PHA) 
and 10 U/ml IL-2 were added 24 hours later.  Proliferation assays with 3H-thymidine 
incorporation were measured at 72 hours and cell numbers were determined with a 
Coulter counter (see Appendix E). 
 
To confirm the specificity of cloned CD4+ T cells, they were stained with 1 µg PE-
labelled tetramer for 3 hours at 37°C in 50 µL of cell culture media.  Cells were washed 
in PBS containing 1% FBS and 0.1% NaN3 and stained with fluorochrome-labeled anti-
CD4 (PharMingen, San Jose, California, USA).  After 30-minute incubation, cells were 
washed again and analysed using the fluorescence-activated cell sorter. 
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These T cell clones were analysed for specific T cell receptor (TcR) typing, peptide-
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MEASURING CYTOKINE SECRETION  
 
To study IFN-  secretion as an indicator of T cell reactivity, PBMCs were stimulated with 
test peptide and assayed on day 10.  After 2 hours of incubation of PBMCs with antigen 
presenting cells and test peptide, cells were washed and processed.  Determination of 
IFN-  secretion required the use of a cytokine secretion capture assay (Miltenyi Biotec, 
Auburn, California).  T cells were stained for IFN-  and FITC-conjugated anti-CD4 
antibody prior to cell flow cytometry analysis.  
 
 
TYPING OF T CELL RECEPTORS (TcR) 
 
T cell clones were analysed by flow cytometry after staining for TcR Vß chains using the 
Beckman-Coulter IO Test BetaMark TCR ß Repertoire Kit, which has 24 Vß-specific 
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TETRAMER STAINING OUTCOME 
 
Initial cell incubation protocol required addition of peptide-loaded monomer at day 10 in 
an attempt to increase secondary tetramer staining intensity.  However this was found to 
be unnecessary as direct tetramer staining alone at day 13 had similar effects.  
 
HLA typing was done in 143 prostate cancers and 12 control volunteers (Table 3).  With 
HLA typing data, the following number of patients underwent MHC class II tetramer 




  Table 3: HLA typing of study participants (total n=155) 
 





DRB1*0401 12 3 
DRB1*0701 1 0 
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The protocol was modified and eventually worked on the following types of human T 
cells: CD4+, CD4+CD25- to exclude potential T regulatory/suppressor effects, 
CD4+CD25-CD45RA+ naïve T cells and CD4+CD25-CD45RO memory T cells (Figure 
8).  The PBMCs were single cell sorted using CD4, CD25, CD45RA stains.  The 
CD4+CD25-CD45RA+ naïve T cells and CD4+CD25-CD45RO memory T cells were 
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Figure 8:   Sorting of T cells by MACS microbeads and FACS cell flow 
 cytometry.  T cells are stained with anti-CD4, anti-CD25 and 
 anti-CD45RA. 
 
 T cells are single-cell sorted into (A) CD4+ T cells,  
 (B) CD4+CD25- T cells, (C) CD4+CD25-CD45RA+ naïve  
 T cells and CD4+CD25-CD45RO memory T cells.  
 (D) In this sample, the percentage of CD4+CD25- T cells 
 sorted into CD4+CD25-CD45RA+ naïve T cells is 13.8% and  
 CD4+CD25-CD45RO memory T cells 35.6% respectively. 
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In this study, MHC class II tetramer positive cells in DRB1*0401 prostate cancer patients 
that recognised PAGE-113-25, PAP22-34 and PSMA459-473 were detected (Figures 9 to 13).   
 
Amongst study participants, a total of three prostate cancer patients (aged 64, 65 and 77 
years old) and one healthy control volunteer (60 year old in Figure 14) with HLA 
DRB1*0401 had positive staining by the MHC class II tetramer to detect antigen-specific 
CD4+ T cells.  These positive staining results are listed from Figures 9 to 14.  Our 
assessment of negative controls using either DMSO-loaded tetramer or empty tetramer 
showed similar results.   
 
Figure 9 shows antigen-specific CD4+CD25-CD45RA+ naïve T cells obtained from a 
64-year old prostate cancer patient that specifically bind to the PAGE-113-25 peptide-MHC 
class II tetramers. 
 
Figure 10 shows antigen-specific CD4+CD25-CD45RA+ naïve T cells from another 65-
year old prostate cancer patient that specifically bind to the PAP22-34 peptide-MHC class 
II tetramers. 
 
Figure 11 shows antigen-specific CD4+CD25-CD45RA+ naïve T cells from a 77-year 
old prostate cancer patient that recognises the PSMA459-473 peptide-MHC class II 
tetramers. 
 
 Detecting cancer-specific peptides in prostate cancer   













Figure 9:   A 64 year old prostate cancer patient with six-fold increase in  
  positive staining intensity of the (A) DRB1*0401/PAGE-113-25 tetramer 
   compared to the (B) control.  Note that it occurred only in the  
  CD4+CD25-CD45RA+ naïve T cell population. 
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Figure 10:   A 65 year old prostate cancer patient also had positive staining 
  of the (A) DRB1*0401/ PAGE-113-25 tetramer and the  
   (B) DRB1*0401/PAP22-34  tetramer in the CD4+CD25-CD45RA+ 
   naïve T cell population.  
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Figure 11:  A 77 year old prostate cancer patient with six-fold increase in 
  positive staining intensity of the (A) DRB1*0401/ PSMA 459-473  
  tetramer and the (B) DRB1*0401/ PAP 22-34 tetramer.  Similarly,  
  this occurred only in the CD4+CD25-CD45RA+ naïve T cell 
  population.  
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For these prostate cancer patients, it is noted that only CD4+CD25-CD45RA+ naïve T 
cells are reactive while the CD4+CD25-CD45RO memory T cells are not reactive 
(Figures 12 and 13).   
 
When compared to the positive HA-peptide controls in Figure 13, the CD4+CD25-
CD45RA+ T cells in Figure 12 are the only TH populations that stained strongly. 
 
In a healthy DRB1*0401 control, PAGE-113-25 is also recognised and detected by the 
MHC class II tetramer (Figure 14).   
 
Figure 14 shows antigen-specific CD4+CD25-CD45RA+ naïve T cells from a 60-year 
old normal control volunteer that specifically bind to the PAGE-113-25 peptide-MHC class 
II tetramers.  His CD4+CD25-CD45RO memory T cells did not show positive staining to 
the PAGE-113-25 peptide-MHC class II tetramers.   
 
It is interesting to note that this healthy volunteer had a stronger positive staining for 
PAGE-113-25 peptide-MHC class II tetramers (13.1%) when compared to the prostate 
cancer patient shown in Figure 9 (6.0%).  One possibility is that a greater proportion of 
naïve T cells in the healthy volunteer survived due to weak recognition of PAGE-1 
antigens, which are inadequate to activate them into effector cells. 
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Figure 12:  PAGE-113-25 loaded MHC class II tetramer staining on Day 13 for a 64-year 
  old prostate cancer.  Top panel (A) shows FACS of tetramer staining for  
  CD4+,  CD4+CD25-, CD4+CD25-CD45RA+ and CD4+CD25-CD45RO  
  T cells.  Tetramer positive staining occurred only in the CD4+CD25-CD45RA+ 
  naïve T cell population at 13.0 % (circled).   
 
  Bottom panel (B) shows no positive staining patterns in the negative controls 
  using empty tetramers. 
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Figure 13:  Positive HA control peptide-loaded MHC class II tetramer staining on  
  Day 13 for a 64-year old prostate cancer. Top panel (A) shows positive 
  tetramer staining for CD4+, CD4+CD25-, CD4+CD25-CD45RA+  
  and CD4+CD25-CD45RO T cells when using HA307-319 peptide 
 
  Bottom panel (B) shows staining patterns in negative control using 
  empty- tetramer. 
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 Figure 14:   A 60 year-old healthy normal volunteer also had a positive staining  
  intensity of DRB1*0401/PAGE-113-25 tetramer.  Note that this 
   occurred in the (A) CD4+CD25-CD45RA+ naïve T cell population 
  only.  The memory T cell population in the bottom panel (B) did not 
   show any positive tetramer staining. 
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BACKGROUND STAINING FOR CONTROLS 
 
The background staining of both the positive and negative controls were also analysed in 
relation to status of influenza vaccination to compensate for response to recent 
immunization that may increase reactivity to Hemophilus influenza (HA307–319 influenza 
A hemagglutinin protein, residues 307–319) peptide (Table 4).   
 
In the same individual, background staining using MHC class II tetramers may change 
due to the presence of active influenza, systemic infection, recent foreign antigen 
challenge to the adaptive immunity, or recent influenza vaccination.   
 
This important data is used as a comparison to the staining intensity of any tetramer-
positive T cells for the individual study participant.  If the peptide-MHC class II tetramer 
detects a positive signal, we modified and deducted these positive results with the 
background activities as listed in this Table 4. 
 
This will ensure proper interpretation of tetramer staining signals in relation to 






 Detecting cancer-specific peptides in prostate cancer   





Table 4: Analysis of background staining in normal control volunteers and  
   prostate cancer patients (CaP).  The staining of MHC class II  
   tetramer positive T cells are compared between day 13 and day 16  
   after primary peptide stimulation to assess the level of background  
   staining.   
 
Both positive controls (HA 307-319 peptide) and negative controls 
showed similar background staining when taken on the same day.  
Note that there were variations in background staining in the same 
patient when we compared data between day 13 and day 16 after 




shot Test Date Day 13   Day 16 (+ IL-2) 









             
Normal 1 Sep-02 26-Nov-02 0.74 1.79     
           
CaP 2 None 22-Dec-02 0.52 1.05     
  
(Egg 
allergy) 25-Dec-02     0.6 0.41 
           
Normal 2 Jan-02 31-Dec-02 1.01 1.03     
    3-Jan-03     0.59 1.76 
           
CaP 3 Oct-02 31-Dec-02 1.49 1.22     
           
CaP 4 Oct-02 12-Jan-03 0.88 0.64     
    15-Jan-03     1.45 1.56 
           
CaP 5 Oct-02 21-Jan-03 8.57 7.5     
    24-Jan-03     12.05 13.42 
           
CaP 6 Nov-02 21-Jan-03 0.22 0.13     
    24-Jan-03     3.55 3.55 
           
CaP 7 Oct-02 31-Jan-03 7.92 6.3     
    3-Feb-03     18.52 15.04 
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CD4+ T CELL CLONES 
 
Antigen specific T cell clones were obtained from tetramer-positive staining CD4+ T 
cells after single-cell sorting.  CD4+CD25-CD45RA+ naïve T cell clones of HLA 
DRB1*0401 prostate cancer patients that recognised PAGE-113-25 were isolated, 
expanded and studied (Figures 15). 
 
Specific peptide-loaded MHC class II tetramers were used to analyse the specificity of 
the T cell clones.  During T cell expansion we confirm the antigen specificity before 
selection for phenotypic and cytokine assays.  In figure 15, T cells clones obtained from a 
prostate cancer patient were stained positive with the MHC class II tetramers, as shown 
by P315.RA.4A, P315.RA.5A and P315.RA.6A.   
 
Comparatively, P315.RA.1B and P315.RA.1C clones were not identified using the 
specific peptide loaded MHC class II tetramer.  Confirmation of the expanded T cell 
clones was done using the peptide-specific tetramers during the process of T cell culture 
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 Figure 15:   CD4+CD25-CD45RA+ naïve T cell test clones for a 65 year old  
   prostate cancer patient.   
 
   Top row (A) represents cell populations that are not clones since  
   they are not positively stained in the presence of peptide-loaded  
   MHC class II tetramers 
 
   Bottom row (B) shows T cell clones that are positively stained  
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Compared to negative controls, cytokine assays on these antigen-specific T cell clones 
showed increased tumour-necrosis factor-alpha (TNF-α, IFN-γ and IL-2 at 24 hrs after 
peptide stimulation, which identifies it as a functional TH1 subset (Figure 16).   
 
Cytokine secretion capture assays (Miltenyi Biotec, Auburn, California) showed that to 
produce TNF-α and IFN-γ, all 3 components of T cell clones that specifically recognise 
peptides and antigen presenting cells must be present.  This implies that the interaction is 
highly antigen-specific and any missing component will not activate the CD4+ T cell 
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 (A)       
   

































Figure 16:   Phenotype of CD4+ T cell clone.  
 
(A) Using DR0401/PAGE-113-25 tetramer, only CD4+ T cell clone  
P005.4B (and not P005.4A) has confirmed clonal specificity to p1102 
(PAGE-113-25) peptide.  
 
(B) Cytokine assays on PAGE-113-25 peptide-specific T cell clone  
P005.RA.4B (pep) showed increased TNF-α, IFN-γ and IL-2 
production when compared to negative empty-tetramer control (ctrl). 
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Figure 17:  Cytokine production of CD4+ T cell clone that recognises  
  PAGE-113-25 epitope.   
 
  The left most column labelled “peptide (PAGE-113-25)”   
  includes antigen-specific CD4+ T cell clone for PAGE-113-25 
  peptide, irradiated autologous antigen presenting cells (APC) 
  and the PAGE-113-25 peptide.   
 
  All 3 components are needed for the stimulus to produce  
  TNF-α and INF- γ. 
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The proliferative capacity of T cells was analysed using the [3H]-thymidine incorporation 
assay.  Figure 18 showed that proliferation of these tetramer positive PAGE-113-25 
peptide-specific CD4+ T cell clones (P005.RA.4B) were PAGE-113-25 peptide 
concentration-dependent.   
 
For T cell clone P005.RA.4B that recognised PAGE-113-25 peptide, higher peptide 
concentration at 10 µg/ml stimulated increased responses when compared to lower 
peptide concentration at 0.1 µg/ml.  There were minimal responses in the non-clonal T 
cells (P005.RA.4A) and control peptide. 
 
Figure 19 shows T cell receptor (TcR) typing of one of the T cell clones using the 
Beckman-Coulter IOTest BetaMark TcR typing kit.  This shows that the P315.RA.5A 
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Figure 18:    Clonal T cells, P005.RA.4B, respond to specific peptide  
  stimulation (PAGE-1) in a peptide concentration-dependent  
  manner. 
 
  P005.RA.4B is a positive T cell clone that recognizes PAGE-1  
  peptide using PAGE-113-25 -specific MHC class II tetramer.   
  P005.RA.4A cells do not recognise PAGE-1 peptide.  Note that  
  P10 = PAGE-1 peptide at 10 µg/ml while C10 = control peptide  
  at 10 µg/ml 
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Figure 19:   P315.RA.5A CD4+CD25-CD45RA+ naïve T cell clone.  This was 
done using the commercial Backman-Coulter IOTest BetaMark TcR 
typing kit. (A) Positive staining using the typing kit identified the 
positive TcR marker (circled). (B) Repeating the test using the test kit 
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DEVELOPMENT OF TETRAMER STAINING PROTOCOL 
 
This is a challenging project because during the design of this study, there was no 
published literature or established protocols to work on cancer-specific peptides using 
biotinylated MHC class II tetramers.  Protocols were modified and developed in relation 
to prior MHC class II tetramer workflow on auto-immune diseases. 
 
As highlighted in the methods section, compared to the original protocol for autoimmune 
disease, the current protocol does not require HLA-DR monomer loaded with the test 
peptide for secondary stimulation [24].   
 
In addition, day 1 in vitro primary stimulation with test peptides was done in cell-sorted 
mononuclear cells in the following 4 types of CD4+ T cells:   
 
• CD4+ T cells 
• CD4+CD25- T cells to remove potential confounding T regulatory or T 
suppressor effects 
• CD4+CD25-CD45RA+ naïve T cells, and  
• CD4+CD25- CD45RO memory T cells 
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These 4 types of CD4+ T cells were studied to analyse their presence during the phases of 
adaptive immune responses after antigen exposure.  These phases start from the antigen 
peptide recognition phase with clonal expansion of naïve T lymphocytes to the activation 
and effector phase where T cells undergo differentiation for elimination of antigens by 
cell-mediated immunity.   
 
Regulatory CD4+CD25+ T cells, also known as T suppressor cells, maintain 
immunological self tolerance and may reduce the activation of tumour-specific effector T 
cells in recognising autologous tumour cells [36].  Self-reactive CD4+CD25- T cells had 
previously responded to self-peptides and MHC class II MHC molecules on autologous 
antigen presenting cells [37].   
 
Hence this study aims to look at the CD4+CD25- T cells, without the suppressive effects 
of T regulatory cells, for peptide-specific T cells to prostate cancer-associated peptides. 
 
The presence of effector T lymphocytes is shown by positive CD45RA+ marker for naïve 
T cell populations.  The immune response normally reduces towards baseline when the 
antigen-stimulated T cells undergo apoptosis while the antigen-specific memory T cells, 
which are CD45RO T cells, survive longer.  Hence this study also aims to detect memory 
T cells, if any, that have achieved longer-term survival after response to a prostate 
cancer-associated peptide. 
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MHC CLASS II TETRAMER STAINING 
 
Preliminary HLA typing was done in 155 study participants, consisting of 143 prostate 
cancers and 12 control volunteers.  Table 3 summaries the number of participants who 
had additional blood withdrawal for fresh PBMCs to isolate the CD4+ T cells for primary 
peptide stimulation and subsequent MHC class II tetramer analysis. 
 
The presence of CD4+ T cells is vital to maintain and sustain CD8+ T cell numbers, 
allowing CD8+ T cells to infiltrate into the tumour [38].  Absence of CD4+ T cells allows 
tumour progression and co-transfer of CD4+ T cells facilitates tumour lysis.  CD4+ T 
cells also secrete IL-2 and other cytokines for macrophage migration and CD8+ anti-
tumoral cytotoxicity. 
 
Hence an understanding of specific CD4+ T cell epitopes directed against prostate 
cancer-specific antigens is necessary.  This understanding will allow appropriate vaccine 
design for peptide-based vaccines directed against prostate cancer.   
 
Prostate cancer is a weakly immunogenic solid tumour.  Antibodies and reactive T cells 
directed against prostate malignancy are detected after clinical vaccination with prostate 
cancer associated peptides.  Evaluation of a cohort of 200 prostate cancer patients at 
different stages of cancer showed the presence of humoral immune responses against 
prostate specific antigen (PSA), prostatic acid phosphatase, p53 and HER-2/neu [39].   
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Interestingly, antibody immunity to PSA was significantly different between the prostate 
cancer patients and normal controls.  High antibody titres were seen even in those with 
androgen-independent prostate cancers, suggesting that immune responses to prostate 
cancer occurred at any stage of the disease.   
 
Both B cells and T cells immune responses to prostate cancer were also detected.  
Immuno-competent prostate cancer patients who were treated with autologous, irradiated 
granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting gene-transduced 
cancer vaccines induced anti-tumour effects in a phase I human gene therapy trial [40]. 
 
When analysing a MHC class I-deficient murine model tumor-associated antigen (β-
galactosidase), MHC class II-mediated antigen presentation allows antigen-specific 
immunity against in vivo prostate cancer.  MHC class I-restricted antigen presentation 
and cytotoxic activities are not adequate for vaccinia immunisation to induce protective 
immunity against tumours low in MHC class I molecules [41]. 
 
In view of prostate cancer immunogenicity, this study aims to find useful novel prostate 
cancer-specific peptide recognised by helper CD4+ T helper cells which help to stimulate 
cytolytic CD8+ directed T cells killing of cancer cells.  
 
Antigen recognition by T lymphocytes requires specific and integrated intercellular 
signals for activation [42].  Successful signal cascades between antigen presenting cells 
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and T cells require multiple co-existing factors like intact MHC-T cell receptor (TCR) 
complexes, co-stimulatory factors and adhesion molecules. 
 
Amongst all participants, three prostate cancer patients (aged 64, 65 and 77 years old) 
and one healthy control volunteer (60 year old in Figure 14) had positive staining by the 
MHC class II tetramer to detect antigen-specific CD4+ T cells.  Figures 9 to 13 show that 
MHC class II tetramer positive cells were detected in DRB1*0401 prostate cancer 
patients and normal control, with the ability to recognise PAGE-113-25, PAP22-34 and 
PSMA459-473 peptides.   
 
Figure 9 shows antigen-specific CD4+CD25-CD45RA+ naïve T cells from a 64-year old 
prostate cancer patient that specifically bind to the PAGE-113-25 peptide-MHC class II 
tetramers.  Prostate associated gene-1 (PAGE-1) is a prostate associated cancer-testis 
antigen [33].  It is an X-linked gene and belongs to the human cancer-testis antigens 
family.   
 
PAGE-1 has been found in the prostate, testes and uterus in both normal controls and 
cancer patients.  The family of cancer-testis antigens, which has an expression pattern of 
the melanoma antigen gene (MAGE) family, is an attractive chief target for antigen-
specific immunotherapy because of their ability to mount antigen-specific T cell 
responses [43]. 
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Figure 10 shows antigen-specific CD4+CD25-CD45RA+ naïve T cells from another 
prostate cancer patient that specifically recognise the PAP22-34 peptide.  Prostatic acid 
phosphatase (PAP), although found in the prostate and semen, is not specifically located 
in the urogenital system.  It is not prostate-specific and is also be found in the bone, liver, 
spleen and kidneys.  In a randomised Phase II clinical trial, loaded dendritic cell therapy 
using prostatic acid phosphatase (APC8015; Provenge®, Dendreon Corp, Seattle, WA) 
as an immunogen had shown a modest survival benefits of 4.5 months in patients with 
metastatic hormone-refractory prostate cancer [44].   
 
Figure 11 shows antigen-specific CD4+CD25-CD45RA+ naïve T cells from a prostate 
cancer patient that recognise the PAP22-34 and PSMA459-473 peptide-MHC class II 
tetramers.  Prostate-specific membrane antigen (PSMA) is a transmembrane folate 
hydrolase associated with increased expression in prostate cancer.  The over-expression 
of PSMA is found in higher Gleason grade prostate cancer tumours, in the presence of 
distant metastases and in patients with earlier biochemical disease recurrence [45].   
 
For prostate cancer patients, it is noted that only CD4+CD25-CD45RA+ naïve T cells are 
reactive while the CD4+CD25-CD45RO memory T cells are not reactive (Figures 12 and 
13).  When compared to the positive HA-peptide controls in Figure 13, the CD4+CD25-
CD45RA+ T cells in Figure 12 are the only TH populations that stained strongly. 
 
One possibility is that despite initial cancer-specific epitope recognition, the TH cells are 
unable to convert this data into long-term memory T cell repertoire, thereby allow cancer 
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cells to escape immuno-surveillance with disastrous outcome to multiple and develop 
clinical symptomatic cancer.   
 
Another possibility is the arbitrary gating of CD4+CD25-CD45RA+ and CD4+CD25-
CD45RO T cells during single cell sorting before primary peptide stimulation.  Single 
cell gating techniques using additional FoxP3 and CD62L markers could contribute to 
better specificity.   
 
In addition, cancer cells may have developed several escape mechanisms to evade 
immune destruction.  Transformed malignant cells can express novel cell surface antigens 
but are not being perceived as non-self by the immune system [46].  Several other ways 
of immune escapes include deficiency in MHC class I molecules, lack of co-stimulatory 
molecules for successful T cell activation and lack of adhesion molecules for proper 
MHC-TCR complex formation.  Other tumour cells may secrete suppressive cytokines 









 Detecting cancer-specific peptides in prostate cancer   
using MHC tetramer technology 
 
81 
USES OF PEPTIDE EPITOPES AND ANTIGEN-SPECIFIC T-CELLS 
  
When specific epitopes are detected in the prostate cancer and controls subjects (e.g. 
PAGE-113-25 peptide), this is postulated as a prostate-associated peptides recognised by 
circulating CD4 T cells, as highlighted in our article [47].  However, it is likely to be a 
weak immunogen, similar to many tumour antigens.  Since the host CD4 T cells can bind 
and recognise it in its MHC class II-PAGE-1-TcR complex, we can modify PAGE 113-25 
protein as a potential peptide epitopes for vaccine design.  Future studies using in vitro 
priming with PAGE 113-25 protein with subsequent titration assays could assess its 
immunogenicity. 
 
Figure 14 shows antigen-specific CD4+CD25-CD45RA+ T cells from a 60-year old 
normal control volunteer which bind to the PAGE-1 peptide-MHC class II tetramers.  
Hence, in a healthy DRB1*0401 control, PAGE-113-25 is also recognised and detected by 
the MHC class II tetramer (Figure 14).  This implies that upon activation, the non-
memory effector T cells are capable to recognising PAGE-1 peptide.  Both prostate 
cancer patients and normal controls have the ability to recognise these subsets of CD4+ T 
cells.   
 
To design prostate cancer vaccines, one possible way is to use PAGE-113-25 with 
autologous antigen presenting cells from prostate cancer patients.  These patients should 
have antigen-specific CD4+ T cells that recognise PAGE-113-25 peptide-loaded MHC 
class II tetramers.  Using an exogenous PAGE-113-25 peptide-pulse approach, this will 
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stimulate T cell responses without autoimmune self destruction, thereby increasing the 
CD4+ effector T cell responses to increase CTL activities and improve destruction of 
prostate cells expressing PAGE-1 antigens.  However it is important to note that since 
normal prostatic cells also express PAGE-113-25, potential auto-immunity to normal 
prostate may occur. 
 
The possible role to use this peptide-MHC class II interaction to monitor CD4+ T cell 
response should be analysed in the future.  It may be used as a surrogate marker to 
monitor efficacy of CD4+ T-helper cell activation in future prostate cancer clinical 
vaccine trials.  Further analysis on its tetramer staining levels in different disease stages 
of  prostate cancer and normal healthy volunteer controls must be done before clinical 
applications. 
 
None of the activated memory CD4+ T cells were stained positive using the MHC class 
II tetramers.  It is not surprising because these are self antigens occurring in normal body 
tissues that should not be attacked by self.  Absence of longer-term memory T cell 
response implies that any increase in these self antigens will only cause temporary 
increase in T-helper effector cells for short-term effects. 
 
Several potential antigen-specific CD4+ T cell epitopes were identified in DR0401 
individuals, including PAGE-113-25, PAP 22-34 and PSMA 459-473.  These peptides may also 
be loaded onto MHC class II tetramers to detect the antigen-specific CD4+ T cells when 
patients undergo immunotherapy to monitor their CD4+ T cell responses. 
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Even though many tumour-specific MHC class I CD8+ CTL epitopes are known, only a 
few tumour-specific MHC class-II CD4+ TH cell epitopes have been identified in 
malignancies (e.g. melanoma).  It is important to identify tumour-associated epitopes 
presented by MHC class II molecules because they will activate CD4+ TH cells to induce 
and maintain CD8+ CTL killer effects [48]. 
 
It is interesting, though not surprising, that all the PSA peptide sequences tested (e.g. 
PSA49-63, PSA64-78, PSA79-91, PSA200-212) were not recognised by the MHC class II 
tetramers.  Since PSA is easily found in circulating blood and prostate tissues, it is 
recognised as self by the TH cells without the ability to destroy its own prostate.   
 
Hence, this may explain the difficulty when using PSA protein sequences for prostate 
cancer vaccine design and clinical trials.  The immune system is unable to mount an 
effective army of memory T cells for sustained systemic efficacy to destroy prostate 
cancer cells.  We need to consider using other epitopes and peptides in novel prostate 
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ANALYSES OF CD4+ T CELL CLONES 
 
Antigen-specific T cell clones were confirmed using tetramer-positive staining CD4+ T 
cells before phenotypic characterisation.  It is important to analyse the expanded T cell 
clones with the peptide-specific tetramers during T cell culture expansion and 
proliferation to ensure clonal status.  
 
The main sources of IFN-γ production comes from the CD4+ TH1 cells and the CD8+ T 
cells.  Figure 16 shows that the T cell clones are functional TH1 subset, with increased 
tumour-necrosis factor-alpha, IFN-γ and IL-2 production after specific peptide 
stimulation. 
 
When the dendritic cells present antigens to the TcRs of CD4+ T cells, the secreted 
interleukin 12 (IL-12) causes paracrine stimulation of the TH1 cells to secrete their own 
TNF-β, lymphotoxin and IFN-γ.  These cytokines will stimulate macrophages to kill the 
foreign antigen that they have engulfed and recruit other leukocytes. 
 
Figure 17 highlights the importance of synergistic interactions between T cells, peptide 
and antigen presenting cells to produce TNF-α and IFN-γ production.  The interaction is 
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The proliferative capacity of T cells in response to stimuli is determined by a radioactive 
assay based on incorporation of 3H-thymidine into newly generated DNA.  The assay in 
Figure 18 analyses the proliferative characteristics of tetramer positive PAGE-113-25 
peptide-specific CD4+ T cell clones (P005.RA.4B), which were PAGE-113-25 peptide 
concentration-dependent.   
 
Figure 19 shows that the T cell receptor (TcR) typing of a T cell clone from a prostate 
cancer patient was Vb13.1.  Each chain of the T cell receptor (TcR) is a member of the 
immunoglobulin superfamily.  Its function to recognise specific epitopes presented by the 
MHC molecule [49].  
 
It contains an N-terminal immunoglobulin (Ig) variable (V) domain, an Ig constant (C) 
domain, a transmembrane region and a short cytoplasmic tail at the C-terminal end.  The 
variable domain of the TcR α-chain has 3 hypervariable or complementarity determining 
regions (CDRs) while the variable domain of the TcR β-chain has 4 CDRs.  The CDRs 
are responsible for peptide recognition, where the CDR3 is the main CDR responsible for 
this function. 
 
To generate TcR,  the α-chain is generated by VJ recombination while the β-chain is 
generated by V(D)J recombination. Similarly, generation of the γ-chain involves VJ 
recombination while generation of the δ-chain occurs by V(D)J recombination.  
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The intersection of these specific regions (V and J for the alpha or gamma chains; V, D 
and J for the beta or delta chains) corresponds to the CDR3 region for antigen-specific 
MHC molecule recognition.  The combination of CDR3 segments with palindromic and 
random nucleotide additions accounts for the varied repertoire of TcR specificity.   
 
To better define the T cell clonal population, further studies by spectratyping of T cell 
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CONCLUSION AND FUTURE DIRECTIONS 
 
In this study, MHC class II tetramers loaded with specific test peptides are able to detect 
antigen specific T cells in appropriate HLA subjects.  This is a useful tool to identify 
immuno-dominant epitopes for different MHC restriction. 
 
Future studies can be designed to analyse novel peptide sequences and compare its 
clinical utility to serum PSA.  New peptide vaccines trials may use PAGE-1 or PSMA in 
DR0401 patients to monitor immunological responses to injected vaccines.   
 
The ability to identify peptide-specific CD4+ T cells allows monitoring of TH cell 
responses in clinical vaccine trials involving prostate cancer patients and control 
volunteers.  We can further investigate and identify ways to modify long-term memory T 
cell development which will ensure life-long systemic immunotheraputic advantage for 
prostate cancer management. 
 
The design for peptide vaccine should include both the HLA class II-restricted CD4+ TH 
cell epitopes and the HLA class I-restricted tumour-associated CD8+ CTL epitopes for 
maximal synergistic efficacy.  In view of the current limited data on antigen-specific T 
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Original Tetramer staining protocol 
 
Isolation of PBMC from peripheral blood   
 
1. Dilute 20 ml heparin blood 1:1 with 1X PBS in a 50 ml vial  
2. Under layer with 10 ml Ficoll slowly with a 10 ml pipette  
3. Spin down the vials for 20 min at 2000 rpm 
4. Collect the mononuclear cells at the interface 
5. Wash the cells three times with 1 x PBS. If necessary, lyse the RBCs with 
hemolytic buffer. 
6. Resuspend the cells at a density of 5x 106 cells/ml in culture medium  
 
Culture medium: RPMI 640 supplemented with 2 mM L-glutamine, 100 µg/ml 
penicillin/streptomycin, 1 mM sodium pyruvate and 15% pooled human serum 
obtained from 20-25 healthy, non-transfused male donors.  
 
 
Stimulation of PBMC by peptide (e.g. GAD65) and tetramer staining  
 
1. Divide the cells on 24-well plates at 5 x 106 cells with 1 ml TCM in each well. 
2. Add test peptide (e.g. GAD65) at the concentration of 10 µg/ml to another 1 ml 
TCM. (i.e. add 2 µl peptide into 1 ml TCM) 
3. Leave some wells without test peptides (control wells) and incubate the cells at 
37oC for 10 days. 
 
4. From day 7, feed cells with fresh TCM and 1:20 IL-2 if needed. 
 
5. On day 10, count the cells (you can pool the wells containing the same peptide) 
and prepare 48-well micro titer plates used in the secondary stimulation.  Place 
test HLA-DR monomer into each well with 1.5 x 106 cells.  The concentration of 
the monomer should be 10 µg/ml in PBS in a volume of 200 µl/well. (i.e. add 2 µl 
test-monomer into 200 µl TCM, then place into incubator) 
6. Let the monomer bind onto the plates for 3 hours at 37oC incubator. 
7. In the meantime spin down the cells from primary culture (counted above) at 
1,000 rpm, 5 min at RT.   
8. Re-suspend them in 15% TCM containing 1-2 µg/ml anti-human CD28 antibody 
at density of 1.5x106 cells in 400 µl TCM. 
9. Remove monomer-coated plates from incubator and aspirate the TCM. 
10. Carefully add 400 µl fresh TCM into wells and aspirate again.  
11. Transfer the cells (with anti CD28 Ab) onto the monomer plates at 400 µl/well.  
12. Incubate the cells at 37oC for another 3 and 6 days.  
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13. At 48 hours (day 12) take 100 µl of supernatant from each well. Replace with 
100 µl fresh TCM with 1:20 IL-2. (i.e. add 100 µl of IL-2 to every 2 ml TCM) 
14. Freeze the supernatants in cryovials at –80 oC for cytokine analysis. 
 
15. On day 13 of the culture, collect the first set of cells for FACS analysis.  Spin 
them down for 5 min at 1,000 rpm, RT.  
16. Resuspend the cell pellet in 100 µl culture medium 
17. Divide the cell suspension into two flow cytometry tubes (i.e. 50 µl TCM/tube) 
18. Add 2 µl PE-labeled peptide-specific HLA-DR tetramer into each tube (final conc. 
10ug/ml) 
19. Add 2 µl PE-labeled control-specific (e.g. HA, HSV, DMSO) HLA-DR tetramer 
into each tube (final conc. 10ug/ml) 
20. Cover the rack with foil to protect from direct light. Stain the cells with tetramer 
for three hours at 37 oC incubator in darkness. 
21. Transfer the tubes to ice.  
22. Add 5 µl of antibodies specific for human CD4 and T-cell activation marker 
CD25 (labeled with fluorochromes other than PE). 
23. Use 50 –100 000 cells as single-color, unstained controls for FACS analysis.  
24. Stain the cells for 30 min in the dark at RT.  
25. Wash the cells with cold FACS buffer at 1,000 rpm, 5 min at 4 oC, low brake.  
26. Remove supernatant and resuspend cells in  200 µl FACS buffer for analysis by 
flow cytometry.  
 






(1) Ficoll = LymphoprepTM (280 +/- 15 mOsm) 
 
(2) 15% TCM (Nalgene 500ml, 0.2 ul filtered container) 
 
250 mls RPMI medium 1640 with L-glutamine  (Invitrogen Corp, GibcoTM) 
250 mls  15% Pooled human serum (PHS) 
3 mls (Q) L-glutamine 200 mM (100X)   (Invitrogen Corp, GibcoTM) 
3 mls MEM sodium pyruvate solution 100mM (100X) (Invitrogen Corp, GibcoTM) 
3 mls Penicillin-Streptomycin    (Invitrogen Corp, GibcoTM) 
- has 5,000 units/ml Pen-G and 5,000 µg/ml streptomycin sulfate 
 
(3) FACS buffer 
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Draw 150mls heparinised whole blood.  
 
 
Isolation of PBMC from peripheral blood: 
 
Process the 150 ml blood as usual, briefly, dilute 1:1 with sterile PBS, underlay with 10 
ml Ficoll slowly (add Ficoll last).  Centrifuge in covered holders at 2,000 rpm for 20 
minutes (room temp, no brakes).  Harvest interface and combine 2, 1st wash with 50 ml 
PBS by cent. 1,500 rpm x 10 minutes (room temp, low brake). Add warm 5 ml hemolytic 
buffer to condensed cells. Wait 5 minutes. Do 2nd wash by cent 1,000 rpm x 10 minutes 
(RT, high brake), & 3rd wash by cent 1,000 rpm for 5 minutes (RT, high brakes).  Pool all 
pellets with 10 ml MACS running buffer in a 50-ml tube. Count the cells.   
 
 
Isolation of CD4+/CD25- T cells:   
 
5. Wash PBMCs:  If fresh PBMC, wash with MACS running buffer (1X PBS, 0.5M 
EDTA at pH 8, 0.5% BSA) in 50-ml tube. Cent. 1,000 rpm x 7 min (RT, low brake). 
Transfer to 15-ml tube. Wash again.  If stored PMBC overnight, resuspend PBMC 
in 2 ml MACS running buffer, and filter through 0.45 nm filter into 50 ml tube. 
Cent. 1,000 rpm x 7 min (RT, low brake).  
 
6. Add MACS running buffer (4 µl buffer per 106 cells) - estimate cells:Ab:MACS 
buffer = 1:1:4 in µl. Add biotin-Ab cocktail (transparent), and place in cold 40C 
fridge x 10 min. Add another 3 µl MACS running buffer per 106 cells.   
 
7. Add anti-biotin microbeads (yellow) - estimate cells:microbeads = 1:2 in µl. Place 
in cold 40C fridge x 15 min. Wash with 10 ml MACS running buffer, cent. 1,000 
rpm x 7 min (RT, low brake). Resuspend in 5 µl MACS running buffer per 106 cells.  
 
8. Prepare Auto-MACS, MACS running and MACS rinsing buffers. Use “Deplete”, 
CD4+ (unlabelled, negative), APC/others (labeled, positive), and 2 empty 15 ml 
tubes. Note to add extra 1 ml running buffer to cell pellet during suction. Choose 
“Separate”, “Deplete”, “OK”. After separation, choose “Qrinse”. If 2nd sample, 
choose “separate” again. If finished, choose “Sleep”, “Off”, and change new 70% 
ethanol in 15 ml tube.  
 
9. Wash cells in 10 ml warm 15% TCM.  
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10. Suspend in 1 ml TCM and count cells in both tubes (“CD4+” versus “APC/others”).   
Count CD4+ and APC cells. 
 
 
Staining with CD45RA FITC / CD25 PE / CD4 Cy-Chr:  
 
11. Use sterile capped polystyrene 5-ml tubes.  For isotype (irrelevant for all 
fluorochromes) and compensation tubes - add 5 µl samples, 5 µl fluorochromes and 
45 µl 15% TCM.   
 
12. Add all fluorochromes (non-irrelevant for CD45RA FITC, CD25 PE, CD4 Cy-Chr) 
into separate tube with the rest of CD4+ samples in 5-ml sterile capped polystyrene 
tubes. 
 
13. Place in cold 40C fridge x 30 min.   
 
14. In the meantime, prepare APC-bound 24-well plate: Centrifuge and re-suspend non-
CD4+ cells at 10 x 106 cells/ml of 15% TCM. Add 500 µl of these into each well of 
a 24-well plate (i.e. 5 x 106 cells per well). Incubate at 370C x 60 min. Remove non-
adherent cells with fresh TCM x 2X. Add 500 µl warm 15% TCM.  
 
15. Wash CD4+ T-cells and controls with 2 ml warm 15% TCM, centrifuge 1,000 rpm 
x 7 min (RT, low brake). Add 1.5 mls 15% TCM in each of 8 capped 15-ml 
collection tubes (CD45RA+ and CD45RO cells).  Sort cells on FACS Vantage. 
Estimate 1.5 - 2 hrs to sort each sample.  
 
 
Peptide binding:   
 
16. Prepare test peptides (at 20 mg/ml)  and DMSO (negative control) in 1.5 ml TCM at 
20µg/ml (i.e. Add 1 µl peptide to every 2 ml TCM), to make 10µg/ml fc.  
 
17. After cell sorting, add 3 x 106 CD4+/CD25- T-cells into every 1.5 ml of peptide-
loaded TCM. Place into each well to make up to 2 mls, and incubate at 370C 
incubator x 10 days. 
 
18. From day 7, feed cells with fresh 1 ml TCM with 100 µl of IL-2. On day 7, for non-
20 stim, add IL-2 (ratio 1:20 IL-2: TCM) to 100µl fresh TCM (i.e add 50µl IL-2 to 1 
ml TCM) into these wells. Change TCM when necessary. 
 
19. Feed cells when necessary (remove 1 ml old medium, then add another 1 ml fresh 
TCM with 1:20 IL-2). 
 
20. On day 13, remove cells for tetramer binding & FACS staining. No need cytokine 
analysis.  Use empty (for DMSO) & loaded PE-tetramers for respective empty or 
loaded monomer-stimulated cells. 
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On Day 13 to Day 17: 
 
21. Remove 1 ml TCM from each well. Mix well and remove 100 µl into each 5-ml 
polystyrene tube. Add 4 µl of PE-labelled HLA-DR tetramer (0.5 µg/ml) into each 
well to make final conc. 10 µg/ml – one with tested peptide (e.g. PSA or NY-eso-1) 
and one with negative control peptide (empty-tet). Stand for 2 hours at 37ºC.  





22. Set up flow cytometry tubes. Use wells with no monomer in 20 stimulation for 
isotype control and fluorochrome compensation 
 
- Amp. and quadrant adjustment  1= isotype control (Pharm Hit 3a irr IgG1, k) 
- Fluorochrome compensation 2=CD3 FITC, 3=CD3 PE, 4=CD3 PerCP 
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MHC Class II tetramer staining protocol from  
Benaroya Research Institute at Virginia Mason  
(Source: http://www.benaroyaresearch.org) 
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General T-cell Clone Growing protocol 
 
T-cells are stimulated in cycles of every 10-12 days.  They are stimulated with either 
specific or unspecific irradiated PBL.  The specific is obtained from a donor that will 
have specific epitopes for the T-cells (e.g. DR0401).  Between stimulations the T-cell 
clones are given IL-2 to continue proliferation. 
 
(1) Outline of feeding schedule: 
 
Day 0 - Feed and stimulate with IRRADIATED (7-10 minutes, 5k-7k Rads) specific or 
unspecific PBL.  Fresh PBL is always preferred over thawed. 
 
Day 1 - Add IL-2 10U/mL of cell culture.  Add phytohemaglutinin (PHA 2.5ug/mL, only 
if it was an unspecific stimulation (and only on Day 1). 
 
Day 4 or 5 - Expand and split wells if necessary.  Add IL2 and fresh cell culture media (if 
yellow).  Keep as much of the original media as possible due to presence of original 
feeding PBMCs. 
 
If the cells are crowded and are ready to expand, re-suspend the well and transfer half of 
the well into a new well.  Add same volume of media with 20U per mL IL-2 to each well.  
This ensures that the two wells have ‘half’ fresh media and IL-2 at 10U/mL. 
 
Day 6 or 7 - Expand if necessary, add IL-2 and add fresh culture media (if yellow).  
 
It is important that the cells have time to rest (i.e. no IL-2 added) before the next 
stimulation or any experiment. 
 
Day 10 (to 12+) - Feed with Specific or unspecific irradiated PBL. 
 
(In general, feedings alternate between specific and unspecific PBL) 
 
 
TIPS for giving your cells what they need, during the above growth cycle: 
 
* If you see a bunch of long thin fibroblasts or large dark macrophages, the cytokines in 
the well are not ideal for T-cell growth.  Make the T-cells denser by combining some 
wells.  If they start to undergo apoptosis, please re-stimulate them before Day 10-12 days. 
 
* If the T cells grow and proliferate well, give IL-2 every other day.  If they are split into 
separate wells, add additional IL-2. 
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* If the T cells are resting, ..Your cells are resting when they are rounded and no longer 
slug-like.  Some cells will come to a nice rest but others start to die off before all of them 
come to rest.  Just watch them and be attentive. 
 
* Check the plates for contamination between IL-2 stimulations. 
 




Specific Feeding Unspecific Feeding 
96-well plate 1part clones : 4 parts feeder PBMC 
if 100,000 clones feed with 400,000 
irradiated PBMC 
 
1 part clones : 3-4 parts feeder PBMC 
if 100,000 clones feed with 400,000 
irr. PBMC 
48-well plate 1 part clones: 6-8 parts feeder PBMC 
 
1 part clones : 3-4 parts feeder PBMC 
24-well plate 1 part clones: 6-8 parts feeder PBMC 
 
1 part clones : 3-4 parts feeder PBMC 
 
* When setting up a stimulation, keep the total number of clones and feeders at or less 
than the maximum cells per well (see table below) 
 
Example for unspecific feeding:  In 48-well plate, put 0.25X106 clones and 0.75-
1.0x106 irradiated PBMC. 
 
Example for a specific feeding:  In a 48-well plate, put 0.175-0.2 x 106 clones and 
1.1 -1.6 x 106 irradiated PBMC. 
 
(3) When to expand the T cell clones? 
 
Number of wells per plate Maximum cells per well 
96 500,000 
48 1.5 million 
24 2.5 million 
 
* Wells that are ready for expansion will have no space between the cells, or if layering 
of cells are present.   
 
(4) How much IL-2 and PHA to add? 
 
* IL-2 - add 10U/mL (between 10 – 30 U/ml, depending on the clone) 
* PHA - add 2.5ug/mL (between 1.5 - 5 ug/ml, depending on the clone) 
 
Always assume that previous IL-2 and PHA are utilized completely.  Example: If total 
volume is 1 mL and you add 400 ul fresh media - add 10U IL-2 and 2.5 ug PHA. 
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3H-THYMIDINE INCORPORATION PROLIFERATION ASSAY 
 
1. Use 96 well round-bottom plates, triplicates for T cell clones.  Add 20,000 T cell 
clones per well. 
 
2. Titrate test peptides at 0.1 ug/ml, 1 ug/ml, 10 ug/ml 
3. Titrate control peptide at 0.1 ug/ml, 1 ug/ml, 10 ug/ml 
4. Irradiate DR-matched feeder PBLs (5,500 rad), add 100,000 cells per well 
5. Fill 150 ul per well with 15% TCM  - first add 50 ul clones, then  
- add 50 ul feeder cells, then 
- add 50 ul peptides 
 
6. Do not add IL-2 
7. Place in 37ºC incubator 
8. After 24 hrs, take 100 ul of supernatant for cytokine assay  
9. On day 3, add 1 uCurie of 3H into each well 
10. Incubate in 37ºC incubator 
11. After 12 hrs, prepare for scintillation and counts 
 
 
 
 
